Photocure ASA - Invitation to presentation of new commercial strategy

INVITATION TO PRESENTATION OF NEW COMMERCIAL HEXVIX STRATEGY( )

Oslo, Norway, 27 September, 2011: Photocure ASA (OSE: PHO) invites to a
presentation of the new commercial strategy for Hexvix® on Tuesday 27 September
at 11:00 CET, Hotel Continental, Stortingsgaten 24/26, Oslo.
The presentation will be held by President & CEO, Kjetil Hestdal and COO
Kathleen Deardorff.

The presentation will be made available at www.photocure.no and can be followed
real time on http://webtv.hegnar.no/webcast.php?id=33388



Best regards,

Photocure ASA



Christian Fekete

CFO



About Photocure ASA

Photocure ASA is a worldwide leader in photodynamic technology. Listed on the
Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic
technologies in dermatology and cancer. The company strives to solve unmet needs
by developing new and innovative solutions based on its patented Photocure
Technology(TM). Photocure markets and sells its own products in selected markets
and has developed strong partnerships with leading pharmaceutical companies on a
regional and global basis. Photocure's bladder cancer diagnostic product, Hexvix
is approved in Europe and the US. In addition, the company markets Allumera®, a
photodynamic cosmetic in the US. Setting new standards for diagnosis and
treatment of several different conditions, Photocure Technology(TM) is
continuously being tested for new products and applications in cancer and
dermatology.
Allumera®, Photocure® and Hexvix® are registered trademarks of Photocure ASA.
For more information about Photocure, visitwww.photocure.com.



This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act



[HUG#1550070]